Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody

International Immunopharmacology

Volumn 6, Issue 6, 2006, Pages 880-891

  Li, Jian ^a   Davis, Janet ^b   Bracht, Michelle ^a   Carton, Jill ^a   Armstrong, Jennifer ^a   Gao, Wei ^a   Scallon, Bernie ^a   Fung, Ramie ^b   Emmell, Eva ^a   Zimmerman, Mark ^b   Griswold, Don E ^a   Li, Li ^a  

^a CENTOCOR INC   (United States)

^b Center for Diabetes Advance   (United States)

Author keywords

Anti CD3 antibody; Cytokines; Immune suppression; Islet transplantation; T cells

Indexed keywords

ALANINE; FC RECEPTOR; IMMUNOGLOBULIN G2A; MONOCLONAL ANTIBODY CD3; OKT 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL MODEL; GRAFT SURVIVAL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MITOGENESIS; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RECEPTOR BINDING; SPLEEN CELL; SPLEEN LYMPHOCYTE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, CD95; APOPTOSIS; CELL PROLIFERATION; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MUROMONAB-CD3; PROTEIN BINDING; RECEPTORS, FC; T-LYMPHOCYTES; U937 CELLS;

EID: 33646100995     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2005.12.009     Document Type: Article

References (29)

1. Werlen G., and Palmer E. The T-cell receptor signalosome: a dynamic structure with expanding complexity. Curr Opin Immunol 14 3 (Jun 2002) 299-305
2. Cosimi A.B., Burton R.C., Colvin R.B., Goldstein G., Delmonico F.L., LaQuaglia M.P., et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32 6 (Dec 1981) 535-539
3. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313 6 (Aug 8 1985) 337-342
4. Chatenoud L., Baudrihaye M.F., Chkoff N., Kreis H., Goldstein G., and Bach J.F. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 137 3 (Aug 1 1986) 830-838
5. Abramowicz D., Schandene L., Goldman M., Crusiaux A., Vereerstraeten P., De Pauw L., et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47 4 (Apr 1989) 606-608
6. Alegre M.L., Peterson L.J., Xu D., Sattar H.A., Jeyarajah D.R., Kowalkowski K., et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57 11 (Jun 15 1994) 1537-1543
7. Herold K.C., Burton J.B., Francois F., Poumian-Ruiz E., Glandt M., and Bluestone J.A. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1 (Ala-Ala). J Clin Invest 111 3 (Feb 2003) 409-418
8. Hering B.J., Kandaswamy R., Harmon J.V., Ansite J.D., Clemmings S.M., Sakai T., et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 4 3 (Mar 2004) 390-401
9. Carpenter P.A., Pavlovic S., Tso J.Y., Press O.W., Gooley T., Yu X.Z., et al. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol 165 11 (Dec 1 2000) 6205-6213
10. Leo O., Foo M., Sachs D.H., Samelson L.E., and Bluestone J.A. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci U S A 84 5 (Mar 1987) 1374-1378
11. Alegre M.L., Tso J.Y., Sattar H.A., Smith J., Desalle F., Cole M., et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol 155 3 (Aug 1 1995) 1544-1555
12. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 3 2 (Feb 2003) 123-132
13. Hirsch R., Archibald J., and Gress R.E. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab′) 2 fragments of anti-CD3 monoclonal antibody. F(abs′)2 fragments induce a selective T helper dysfunction. J Immunol 147 7 (Oct 1 1991) 2088-2093
14. Blazar B.R., Jenkins M.K., Taylor P.A., White J., Panoskaltsis-Mortari A., Korngold R., et al. Anti-CD3 epsilon F(ab′) 2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen. J Immunol 159 12 (Dec 15 1997) 5821-5833
15. Anasetti C., Tan P., Hansen J.A., and Martin P.J. Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen. J Exp Med 172 6 (Dec 1 1990) 1691-1700
16. Smith J.A., Tang Q., and Bluestone J.A. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 160 10 (May 15 1998) 4841-4849
17. Buysmann S., Bemelman F.J., Schellekens P.T., van Kooyk Y., Figdor C.G., and ten Berge I.J. Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3. Blood 87 1 (Jan 1 1996) 404-411
18. Wagner C., Hansch G.M., Stegmaier S., Denefleh B., Hug F., and Schoels M. The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes: activation-dependent up-regulation and regulatory function. Eur J Immunol 31 4 (Apr 2001) 1173-1180
19. Dieckmann D., Bruett C.H., Ploettner H., Lutz M.B., and Schuler G. Human CD4 (+) CD25 (+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med 196 2 (Jul 15 2002) 247-253
20. Levings M.K., Sangregorio R., Galbiati F., Squadrone S., de Waal Malefyt R., and Roncarolo M.G. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 166 9 (May 1 2001) 5530-5539
21. Herbelin A., Gombert J.M., Lepault F., Bach J.F., and Chatenoud L. Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J Immunol 161 5 (Sep 1 1998) 2620-2628
22. Ferran C., Sheehan K., Dy M., Schreiber R., Merite S., Landais P., et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 20 3 (Mar 1990) 509-515
23. Chatenoud L., Ferran C., Legendre C., Thouard I., Merite S., Reuter A., et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49 4 (Apr 1990) 697-702
24. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346 22 (May 30 2002) 1692-1698
25. Yu X.Z., Zhu L., Davis J.E., Tso J.Y., Hansen J.A., and Anasetti C. Induction of apoptosis by anti-CD3 epsilon F(ab′)2 in antigen receptor transgenic murine T cells activated by specific peptide. J Immunol 157 8 (Oct 15 1996) 3420-3429
26. Chatenoud L., Primo J., and Bach J.F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158 6 (Mar 15 1997) 2947-2954
27. Popma S.H., Griswold D.E., and Li L. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells. Int Immunopharmacol 5 1 (Jan 2005) 155-162
28. Woodle E.S., Xu D., Zivin R.A., Auger J., Charette J., O'Laughlin R., et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68 5 (Sep 15 1999) 608-616
29. Friend P.J., Hale G., Chatenoud L., Rebello P., Bradley J., Thiru S., et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68 11 (Dec 15 1999) 1632-1637